retatrutide type 2 diabetes trial results 2024 2025 produces up to 30.3% weight loss in Phase 3 Lilly's triple agonist achieves 16.8%
Description
GLP-1 medications are licensed only for type 2 diabetes and weight management, not addiction treatment
[DOI] [PubMed] [Google Scholar] 263.Groop P-H, Dandona P, Phillip M, et al
This study employed a multi-omics approach, integrating transcriptomic, metabolomic, and gut microbiota analyses, to identify key pathways and interactions underlying these metabolic disturbances (Song X
Historia de la investigacin [editar] En la dcada de 1980, Svetlana Mojsov trabaj en la identificacin de GLP-1 en el Hospital General de Massachusetts, donde diriga una instalacin de sntesis de pptidos
Not the abstract data
Exposure GLP-1RA therapy
